Forbes is profiling the development work underway at the "unknown" PTC Therapeutics, one of this year's Fierce 15. The feature focuses on the progress of PTC124 in mid-stage trials for Duchenne muscular dystrophy, noting that it has the potential to address a myriad of other genetic flaws as well.
- read the article on PTC Therapeutics from Forbes
Related Articlex:
Genetic therapy could cure 1,800 diseases. Report
Schering-Plough, PTC to collaborate. Report
PTC inks deal with CV. Report